logo

Dynavax Technologies Corp (DVAX)



Trade DVAX now with
  Date
  Headline
5/7/2018 6:31:30 AM Dynavax Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4/17/2018 9:11:44 AM Dynavax Provides New Durability Of Response Data For SD-101 In Combination With KEYTRUDA In Melanoma
3/15/2018 6:37:20 AM Dynavax Says Acceptance Of Two Data Abstracts For SD-101 In Combination With KEYTRUDA For Presentation At AACR Meeting
3/8/2018 6:38:23 AM Dynavax Technologies FY Net Loss $95.2 Mln Or $1.81/Shr Vs Loss $112.4 Mln Or $2.92/Shr Last Year
3/2/2018 6:32:08 AM Dynavax Technologies Says Stanley Plotkin To Step Down From Board On May 31
2/21/2018 9:38:14 AM Dynavax’s HEPLISAV-B Recommended By CDC Panel On Immunization Practices For Prevention Of Hepatitis B In Adults
1/9/2018 6:06:39 AM Hercules Capital Achieves More Than $880 Mln In New Commitments In 2017
1/8/2018 6:09:18 AM Dynavax Reports Availability Of HEPLISAV-B In The US For Prevention Of Hepatitis B In Adults
12/7/2017 10:48:10 PM New Drugs Approved In November
11/9/2017 4:50:35 PM Dynavax Reports FDA Approval Of HEPLISAV-B For Prevention Of Hepatitis B In Adults
11/3/2017 6:40:45 AM Dynavax Technologies Q3 Net Loss Narrows To $22.1 Mln Or $0.38/shr From $34.7 Mln Or $0.90/shr Last Year
9/25/2017 8:59:27 AM RBC Capital Markets Is Raising Dynavax Technologies Corp (DVAX) 4Q18 Estimate To -0.58 From -0.60
9/25/2017 8:59:08 AM RBC Capital Markets Is Lowering Dynavax Technologies Corp (DVAX) 3Q18 Estimate To -0.60 From -0.58